Dasatinib [dasatinib]
- Terms
-
(18F)-N-(2-chlor-6-methyl-fenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-4-ylamino)thiazol-5-karboxamid
BMS-354825
C22H26N7ClO2S
N-(2-chlor-6-methyl-fenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-4-ylamino)thiazol-5-karboxamid
Sprycel
-
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
BMS 354825
BMS-354825
BMS354825
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
- DUI
- D000069439 MeSH Browser
- CUI
- M0470497
- History note
- 2016 (2004)
- Public note
- 2016; DASATINIB was indexed under PYRIMIDINES and THIAZOLES 2004-2015
Allowable subheadings
- AD
- administration & dosage 13
- AE
- adverse effects 16
- AG
- agonists 0
- AA
- analogs & derivatives 0
- AN
- analysis 1
- AI
- antagonists & inhibitors 0
- BL
- blood 0
- CF
- cerebrospinal fluid 0
- CS
- chemical synthesis 1
- CH
- chemistry 1
- CL
- classification 0
- EC
- economics 0
- HI
- history 0
- IM
- immunology 0
- IP
- isolation & purification 0
- ME
- metabolism 0
- PK
- pharmacokinetics 3
- PD
- pharmacology 10
- PO
- poisoning 0
- RE
- radiation effects 0
- ST
- standards 0
- SD
- supply & distribution 0
- TU
- therapeutic use 23
- TO
- toxicity 1
- UR
- urine 0